LYKALABS vs MARKSANS: Stock Comparison
MARKSANS PHARMA is the larger company by market capitalisation. LYKALABS shows a lower P/E, while MARKSANS PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LYKALABS leads 2; MARKSANS leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LYKALABS | MARKSANS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LYKALABS | MARKSANS |
|---|---|---|
| Live Price | ₹74.83 | ₹294.45 |
| Day Change | 1.19% | -1.24% |
| Volume | 88,556 | 8.18 L |
| 52-Week High | ₹98.9 | ₹350.95 |
| 52-Week Low | ₹44.1 | ₹155 |
| Distance from 52W High | -24.34% | -16.1% |
Valuation
| Metric | LYKALABS | MARKSANS |
|---|---|---|
| Market Cap | ₹308 Cr | ₹13,595 Cr |
| P/E Ratio | 0x | 26.32x |
| P/B Ratio | 2.67x | 4.5x |
| EPS | ₹0.57 | ₹3.47 |
| Book Value | ₹25.12 | ₹67.36 |
| Dividend Yield | 0% | 0.3% |
Growth
| Metric | LYKALABS | MARKSANS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 20.8% |
| EPS Growth (TTM YoY) | 0% | 63.5% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | LYKALABS | MARKSANS |
|---|---|---|
| ROE | -37.11% | 18.2% |
| ROCE | -22.29% | 19.33% |
| Net Margin | -7.81% | 14.16% |
| Operating Margin | -24.74% | 29.29% |
| Debt to Equity | 0.56x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | LYKALABS | MARKSANS |
|---|---|---|
| Promoter Holding | 58.45% | 43.87% |
| FII Holding | 0.15%▼ 0.02 pp | 19.06%▲ 1.59 pp |
| DII Holding | 0.66% | 5.54%▼ 0.65 pp |
| Public Holding | 40.73%▲ 0.01 pp | 31.53%▼ 0.94 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LYKALABS and MARKSANS PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.